21 C.F.R. § 316.4

2020-07-02
§ 316.4 Address for submissions

All correspondence and requests for FDA action under the provisions of this rule should be addressed as follows: Office of Orphan Products Development, Food and Drug Administration, Bldg. 32, Rm. 5271, 10903 New Hampshire Ave, Silver Spring, MD 20993.

[78 FR 35133, June 12, 2013]